Obesity, diabetes, hypertension and dyslipidemia are increasing at alarming rates, alongside parallel increases in the incidence and prevalence of many associated cardiometabolic complications such as stroke, heart failure, renal and liver disease. With varying physician specialties responsible for each disease state, this presents additional complexities when determining optimal holistic treatment choices. Chronic kidney disease (CKD) and non-alcoholic steatohepatitis (NASH) currently offer no approved therapy options often resulting in physicians aiming to treat the underlying cause of disease via comorbidities. Conversely, diabetes has seen a proliferation of therapeutic options enter the market resulting in a myriad of treatment pathways or, in some patient cases, treatment inertia.
Multimorbidity creates additional burden and complexity in disease management to both the physician and patient thus impacting associated outcomes. Our cardiometabolic evidence can offer real-world insights to these challenges alongside physician and patient-reported experiences, healthcare resource utilization, current patient management and any future treatment needs. The homogeneity of our approach allows for thematic analysis across cardiometabolic diseases, across geographies and over time.